OncLive® On Air
Episodes
S6 Ep1: Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers
18 Oct 2021
Contributed by Lukas
Dr. Ilson discusses treatment sequencing for patients with gastric and gastroesophageal junction cancer, the integration of immunotherapy into the fro...
S5 Ep50: Gordan on Growing the Infrastructure for In-House Genomic Testing
14 Oct 2021
Contributed by Lukas
Dr. Gordan discusses the advantages of in-house genomic testing, the transition from external to internal sequencing, and the anticipated effects of t...
S5 Ep49: DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
11 Oct 2021
Contributed by Lukas
Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatmen...
S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
07 Oct 2021
Contributed by Lukas
Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been ...
S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
04 Oct 2021
Contributed by Lukas
Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positi...
S5 Ep46: Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
30 Sep 2021
Contributed by Lukas
Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation t...
S5 Ep45: Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
27 Sep 2021
Contributed by Lukas
Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the stud...
S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer
23 Sep 2021
Contributed by Lukas
Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cerv...
S5 Ep43: Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC
20 Sep 2021
Contributed by Lukas
Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.
S5 Ep42: Neel on Maximizing Research Strides in Oncology
16 Sep 2021
Contributed by Lukas
Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and ...
S5 Ep41: Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer
13 Sep 2021
Contributed by Lukas
Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicitie...
S5 Ep40: Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer
09 Sep 2021
Contributed by Lukas
Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of th...
S5 Ep39: McKay Filters Through Frontline Treatment Considerations in mRCC
06 Sep 2021
Contributed by Lukas
Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuance...
S5 Ep38: Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
02 Sep 2021
Contributed by Lukas
Dr. Sosa discusses the rise in thyroid cancer cases, patient risk factors, the financial challenges associated with long-term treatment and testing, a...
S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS
30 Aug 2021
Contributed by Lukas
Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential u...
S5 Ep36: FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer
26 Aug 2021
Contributed by Lukas
Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, an...
S5 Ep35: Krie and Yuan Talk Toxicity Management in Breast Cancer
23 Aug 2021
Contributed by Lukas
Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for...
S5 Ep34: DFCI Faculty Relay Insight Into Confirmed Rebounds of Cancer Screenings After COVID-19
19 Aug 2021
Contributed by Lukas
Dr. Labaki and Dr. Trinh discuss their research on the recovery of cancer screening tests and its link with potential racial disparities from the COVI...
S5 Ep33: Chachoua on Leveraging Screening Opportunities in Lung Cancer
16 Aug 2021
Contributed by Lukas
Dr. Chachoua discusses key guidelines for lung cancer screening, the psychological and financial implications of screening, and the opportunities of a...
S5 Ep32: Making the Most of Molecular Testing in Breast Cancer
12 Aug 2021
Contributed by Lukas
Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing i...
S5 Ep31: FDA Approval Insights: Isatuximab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
09 Aug 2021
Contributed by Lukas
Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from...
S5 Ep30: Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting
05 Aug 2021
Contributed by Lukas
Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitor...
S5 Ep29: Rariy Reviews In-Home Infusion Initiative in Oncology
02 Aug 2021
Contributed by Lukas
Chevon M. Rariy, MD, discusses how the implementation of telehealth during the COVID-19 pandemic shed light on the need for increased access to care f...
S5 Ep28: Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers
29 Jul 2021
Contributed by Lukas
Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of ...
S5 Ep27: Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer
26 Jul 2021
Contributed by Lukas
Drs Brown and Hussain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in li...
S5 Ep26: FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer
22 Jul 2021
Contributed by Lukas
Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, ...
S5 Ep25: Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL
19 Jul 2021
Contributed by Lukas
Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blin...
S5 Ep24: Mayer on the Optimization of SERDs in ER+ Breast Cancer
15 Jul 2021
Contributed by Lukas
Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palb...
S5 Ep23: Wainberg Weighs In on Advances in HER2+ GI Cancers
12 Jul 2021
Contributed by Lukas
In our exclusive interview, Wainberg discussed factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on...
S5 Ep22: CTCA Leaders Provide Post-Pandemic Predictions in Oncology
08 Jul 2021
Contributed by Lukas
Dr. Rariy, Ms. Brown, and Ms. Greenman discuss how the COVID-19 pandemic has led to a significant delay in cancer diagnoses, impacted the training of ...
S5 Ep21: Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers
05 Jul 2021
Contributed by Lukas
Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.
S5 Ep20: Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer
01 Jul 2021
Contributed by Lukas
Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.